C4 Therapeutics is a biotechnology business based in the US. C4 Therapeutics shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.05 – a decrease of 14.19% over the previous week. C4 Therapeutics employs 145 staff and has a trailing 12-month revenue of around $33.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.05 |
|---|---|
| 52-week range | $1.06 - $11.88 |
| 50-day moving average | $5.93 |
| 200-day moving average | $6.46 |
| Wall St. target price | $15.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.71 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.15 from 2024-11-19
| 1 week (2024-11-15) | -3.71% |
|---|---|
| 1 month (2024-10-22) | -33.17% |
| 3 months (2024-08-22) | -31.52% |
| 6 months (2024-05-22) | -28.45% |
| 1 year (2023-11-22) | 173.03% |
|---|---|
| 2 years (2022-11-22) | -55.76% |
| 3 years (2021-11-22) | 37.04 |
| 5 years (2019-11-18) | N/A |
| Revenue TTM | $33.7 million |
|---|---|
| Gross profit TTM | $-86,745,000 |
| Return on assets TTM | -20.61% |
| Return on equity TTM | -46% |
| Profit margin | 0% |
| Book value | $3.44 |
| Market Capitalization | $333.2 million |
TTM: trailing 12 months
We're not expecting C4 Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, C4 Therapeutics's shares have ranged in value from as little as $1.06 up to $11.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while C4 Therapeutics's is 3.056. This would suggest that C4 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put C4 Therapeutics's beta into context you can compare it against those of similar companies.
C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. ; Biogen MA, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.